The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification
Detection of actionable GAs through MTB molecular screening enabled to treat 8% of patients with matched therapy. Patients treated with matched therapy based on ESCAT tiers I/II had statistically longer PFS and OS, compared with ESCAT tiers III/IV.
Authors
- Antonio Sechi (ORCID: https://orcid.org/0000-0002-1374-1794)
- Joanna Cyrta (ORCID: https://orcid.org/0000-0002-0216-5330)
- Isabelle Guillou
- Cindy Neuzillet (ORCID: https://orcid.org/0000-0001-7037-7477)
- Kenza Nedara
- S. Hescot (ORCID: https://orcid.org/0000-0002-0869-3003)
- Maria Fernanda Setúbal Destro Rodrigues (ORCID: https://orcid.org/0000-0002-3067-9224)
- Céline Callens (ORCID: https://orcid.org/0000-0003-3377-4937)
- Zahra Castel-Ajgal
- Olfa Trabelsi‐Grati
- Elodie Girard (ORCID: https://orcid.org/0000-0001-8737-5371)
- Anne Vincent‐Salomon (ORCID: https://orcid.org/0000-0001-5754-5771)
- Ivan Bièche (ORCID: https://orcid.org/0000-0002-2430-5429)
- Michèle Nijnikoff
- Grégoire Marret (ORCID: https://orcid.org/0000-0003-4525-7777)
- Nicolas Servant (ORCID: https://orcid.org/0000-0003-1678-7410)
- M-P Sablin
- Maud Kamal (ORCID: https://orcid.org/0000-0003-1466-0950)
- Christophe Le Tourneau (ORCID: https://orcid.org/0000-0001-9772-4686)
- Jennifer Wong (ORCID: https://orcid.org/0000-0001-7524-5182)
- Julien Masliah‐Planchon (ORCID: https://orcid.org/0000-0002-5596-3926)
- R. Sanchez (ORCID: https://orcid.org/0009-0000-3258-0159)
- Keltouma Driouch (ORCID: https://orcid.org/0000-0002-0077-4749)
- Dominique Stoppa‐Lyonnet (ORCID: https://orcid.org/0000-0002-5438-8309)
- Diana Bello Roufai (ORCID: https://orcid.org/0000-0002-2817-7866)
- Célia Dupain (ORCID: https://orcid.org/0000-0001-6248-140X)
- Édith Borcoman (ORCID: https://orcid.org/0000-0002-5393-5657)
- Samia Melaabi
- Yves Allory (ORCID: https://orcid.org/0000-0002-5526-077X)
- Amani Asnacios Lecerf
- Kimya Rahmani Narj Abadi
- A. Hamza
- E. Lemaitre
- H. Ghazelian
Institutions
- Délégation Paris 5 (FR)
- Inserm (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Paris Cité (FR)
- Université Paris Sciences et Lettres (FR)
- Université Paris-Saclay (FR)
- École Nationale Supérieure des Mines de Paris (FR)
- Institut Curie (FR)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.esmorw.2024.100092
- Citations
- 1
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.29
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Celgene
- Eisai
- Daiichi Sankyo Europe